PPAR history of research

Similar documents
Lipid/Lipoprotein Structure and Metabolism (Overview)

Pathophysiology of Lipid Disorders

High density lipoprotein metabolism

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism

Lipoproteins Metabolism

Plasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD

Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry

Chapter VIII: Dr. Sameh Sarray Hlaoui


Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Arteriosclerosis & Atherosclerosis


Cholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

Part 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema

Lipids digestion and absorption, Biochemistry II

Niacin Metabolism: Effects on Cholesterol

Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins

Cholesterol and its transport. Alice Skoumalová

N-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP

Lipoprotein Particle Profile

Nature Genetics: doi: /ng.3561

Lipid metabolism in familial hypercholesterolemia

Chapter (5) Etiology of Low HDL- Cholesterol


Regulating Hepatic Cellular Cholesterol

CHM333 LECTURE 34: 11/30 12/2/09 FALL 2009 Professor Christine Hrycyna

Lipoprotein Pathophysiology. Lipoprotein Pathophysiology

Cholesterol Metabolism

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia

METABOLISM of ADIPOSE TISSUE

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC

Lipid Metabolism. Remember fats?? Triacylglycerols - major form of energy storage in animals

Dietary Lipid Utilization by Haddock (Melanogrammus aeglefinus)

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

LIPID METABOLISM. Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI

Paraoxonase Responses to Exercise and Niacin Therapy in Men with Metabolic Syndrome. James Kyle Taylor

Metabolism and Atherogenic Properties of LDL

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM. Triacylglycerol and Fatty Acid Metabolism

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

BIOL2171 ANU TCA CYCLE

Is it really that simple? Alyssa Hasty, PhD Associate Professor Molecular Physiology and Biophysics

Zuhier Awan, MD, PhD, FRCPC

Lipid Metabolism Prof. Dr. rer physiol. Dr.h.c. Ulrike Beisiegel

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS

STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS. R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty

Central role of apociii

3-Thia Fatty Acids A New Generation of Functional Lipids?

Thematic review series: The Immune System and Atherogenesis

Metabolic Syndrome. DOPE amines COGS 163

Leptin deficiency suppresses progression of atherosclerosis in apoe-deficient mice

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 : EFFECTS OF LOW DENSITY LIPOPROTEIN APHERESIS

Tracking a Killer Molecule

Copyright 2017 by Sea Courses Inc.

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

The Role of Apolipoprotein CIII in Coronary Artery Disease. Disclosures

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Metabolism of acylglycerols and sphingolipids. Martina Srbová

Principles of Anatomy and Physiology

Summary and concluding remarks

5. THE ROLE OF LIPIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE: GUIDELINES FOR DIAGNOSIS AND TREATMENT

Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School

Pathology of Coronary Artery Disease

Child born in year /3 will die before parents in US (diabetes)

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:

Diabetes Diabetes mellitus is a chronic disease characterized by elevated blood sugars for months to years. Diabetes is characterized by either: (1) a

The apolipoprotein story

Lipids Board Review. Ira Goldberg, MD New York University School of Medicine. Which of the following is the best initial therapy choice?

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM The LDL Receptor, LDL Uptake, and the Free Cholesterol Pool

Antihyperlipidemic drugs

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Oleuropein and Related Compounds Reduce Atherosclerosis

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009

23.1 Lipid Metabolism in Animals. Chapter 23. Micelles Lipid Metabolism in. Animals. Overview of Digestion Lipid Metabolism in

Lipid Lowering in Patients at High Risk for Cardiovascular Disease

Oxidation of Long Chain Fatty Acids

Hmgcoar AGCTTGCCCGAATTGTATGTG TCTGTTGTAACCATGTGACTTC. Cyp7α GGGATTGCTGTGGTAGTGAGC GGTATGGAATCAACCCGTTGTC

Lipoprotein Formation, Structure and Metabolism: Cholesterol Balance and the Regulation of Plasma Lipid Levels

Nutrition & Wellness for Life 2012 Chapter 6: Fats: A Concentrated Energy Source

Lipid Metabolism in Familial Hypercholesterolemia

THE ROLE OF PPARα AND GROWTH HORMONE IN HEPATIC LIPID METABOLISM AND ATHEROSCLEROSIS. Anna Ljungberg

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

OVERVIEW OF ENERGY AND METABOLISM

TC =96; HDL-C = 21; Non-HDL-C = 75; LDL-C: less than 10 TG: 357; VLDL-C = 71; TG/HDL-C: 17 TC/HDL-C = 4.5

The changes of serum BDNF, blood lipid and PCI in the elderly patients with coronary heart disease complicated with diabetes mellitus

* Author to whom correspondence should be addressed; Tel.: ; Fax:

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

BIOCHEMISTRY. Glycolysis. by Dr Jaya Vejayan Faculty of Industrial Sciences & Technology

BCH 447. Triglyceride Determination in Serum

CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL

Transcription:

PPAR Rubens, 1640

PPAR history of research number of publications 3000 2000 1000 0 till now: : 16 296 publications 1985 1990 1995 2000 2005 year

liver, brown adipocytes, kidney, heart, skeletal muscles, macrophages, foam cells ubiquitously expressed adipocytes, intestine, retina, macrophages, foam cells, endothelium

Peters et al. 2013

PPAR, PPAR, PPAR - Lipid-activated transcription factors - Regulate: * lipid metabolism * glucose homeostasis - Impaired PPAR activity is believed to lead to dyslipidemia and insulin resistance LTB4

Peroxisomes The ubiquitous organelles, delineated by a single membrane, containing ing enzymes that utilize oxygen to subtract hydrogen atoms from organic substrates in an oxidative reaction that generates hydrogen peroxide. Peroxisomes typically contain catalase,, an enzyme that uses H 2 O 2 to oxidize formic acid, alcohols, phenols,, and other substrates.. Any remaining H 2 O 2 present in the cell is broken down by catalase into water and free oxygen molecules. Peroxisomes are responsible for degradation of fatty acids and the catalysis of the initial steps in the synthesis of phospholipids, utilized in membrane formation. peroxisome proliferators

Peroxisome proliferators Peroxisome proliferators are a diverse group of chemicals. Responses of rodent hepatocytes to peroxisome proliferators include prolifera- tion of peroxisomes, increase in -oxidation of fatty acids, resulting from induction of all enzymes in the peroxisomal -oxidation cascade,, and hepatomegaly. The peroxisome proliferator-response response has gained considerable interest due to its association with metastatic hepatocellular carcinomas in rodents. The mechanism is not clear - these compounds do not bind directly and do not damage DNA.

PPARs (peroxisome proliferator-activated activated receptors) PPARs were cloned in 1990 as transcription factors that mediate the effects e of synthetic peroxisome proliferators. Since this time PPARs have been described in a wide variety of species ranging from zebrafish and Xenopus to mouse and human. Danio regio Xenopus laevis The ligand binding pocket of PPARs is much larger than that of other NRs,, with a volume of 1300 Å,, of which the ligand occupies only about 30% to 40%. Overall, PPARs appear to have evolved as NRs adapted for binding to multiple natural ligands with relatively low affinity. The first PPRE was identified in the promoter of the acyl coenzyme A (acyl( acyl-coa) oxidase gene,, and then in a number of genes activated during adipocyte differentiation or associated with lipid metabolism.

PPAR and lipid metabolism In the liver,, PPAR targets form a comprehensive ensemble of genes which participates in many if not all aspects of lipid catabolism. It includes: * transport of fatty acids in the circulation, * their uptake by the hepatocytes, * intracellular binding by fatty acid binding proteins, * activation by the acyl-coa synthase, * -oxidation in the peroxisomes and mitochondria, * -oxidation in the microsomes. Ethanol inhibits PPAR activity it may play a role in development of alcoholic fatty liver.

PPAR -/- mice Overall,, PPAR acts as a global regulator of energy metabolism, which coordinates the rates of utilization of the various energy sources in relation to food availability. Accordingly,, PPAR null mice which are viable and do not exhibit any obvious phenotype when kept under normal laboratory conditions and diet, experience serious difficulties during fasting,, a situation that normally results in an enhanced fatty acid mobilization and increased -oxidation in the liver as fatty acids represent the major energy source. Confronted to such a metabolic challenge, PPAR null mice are not capable of enhanced fatty oxidation and rapidly suffer from hypoglycemia and hypothermia. With age they develop obesity. Mice display increased inflammatory reactions and delayed wound healing.

PPAR participates in the control of the inflammatory response: * it decreases inflammation possibly via stimulation of catabolism of the proinflammatory lipid mediators. * its activation results in repression of NF B signaling which leads to decreased production of proinflammatory cytokines in different celltypes.

Lipoprotein Classes and Inflammation Chylomicrons, VLDL, and their catabolic remnants LDL HDL > 30 nm 20 22 22 nm Potentially proinflammatory 9 15 nm Potentially anti- inflammatory Doi H et al. Circulation 2000;102:670-676; Colome C et al. Atherosclerosis 2000;149:295-302; Cockerill GW et al. Arterioscler Thromb Vasc Biol 1995;15:1987-1994.

PPAR lowers trigliceride levels as a result of: - enhanced lipolysis, induction of FA uptake and catabolism - reduced FA synthesis and VLDL production by the liver - increased removal of LDL

Anabolism Catabolism LDL lymph blood A-I, apo A-I; B, apo B-100; B-48, apo B-48; C, apo C; CE, cholesterol ester; CETP, cholesterol ester transfer protein; CM, chylomicron; CMR, chylomicron remnant; E, apo E; HL, hepatic lipase; LCAT, lecithin:cholesterol acyltransferase LPL, lipoprotein lipase; TG, triglycerides;

Eruptive xanthomas Effect of dyslipidemia

hemorrhage Atherosclerotic plaques Effect of dyslipidemia healthy vessel ~70% lumen reduction calcification occlusive plaque hemorrhage

Atherosclerosis is an Inflammatory Disease Monocyte Vessel Lumen Endothelium Cytokines Growth Factors Metalloproteinases Cell Proliferation Matrix Degradation Foam Cell Macrophage Intima Ross R. N Engl J Med 1999;340:115-126.

Role of LDL in Inflammation LDL Readily Enter the Artery Wall Where They May be Modified LDL Vessel Lumen Oxidation of Lipids and ApoB Aggregation LDL Endothelium Hydrolysis of Phosphatidylcholine to Lysophosphatidylcholine Other Chemical Modifications Modified LDL Modified LDL are Proinflammatory Intima Steinberg D et al. N Engl J Med 1989;320:915-924.

Modified LDL stimulate expression of MCP-1 1 in endothelial cells Monocyte Vessel Lumen LDL MCP-1 LDL Endothelium Modified LDL Intima Navab M et al. J Clin Invest 1991;88:2039-2046.

Differentiation of monocytes into macrophages Monocyte Vessel Lumen LDL MCP-1 LDL Modified LDL Endothelium Intima Macrophage Modified LDL Promote Differentiation of Monocytes into Macrophages Steinberg D et al. N Engl J Med 1989;320:915-924.

Macrophages express receptors that take up modified LDL Adhesion Molecules Monocyte Vessel Lumen LDL MCP-1 LDL Endothelium Modified LDL Taken up by Macrophage Foam Cell Macrophage Intima Steinberg D et al. N Engl J Med 1989;320:915-924.

Modified LDL induces macrophages to release cytokines that stimulate adhesion molecule expression in endothelial cells Adhesion Molecules Monocyte Vessel Lumen LDL MCP-1 LDL Endothelium Cytokines Modified LDL Macrophage Intima Nathan CF. J Clin Invest 1987;79:319-326.

HDL prevent formation of foam cells, reduced adhesion molecules and inhibiti the oxidative modification of LDL Monocyte LDL Vessel Lumen Adhesion Molecules Cytokines MCP-1 LDL Modified LDL Endothelium HDL Inhibit Oxidation of LDL Macrophage Foam Cell HDL Promote Cholesterol Efflux Intima Mackness MI et al. Biochem J 1993;294:829-834.

Mechanisms by which fibrates correct dyslipidemia: - transcriptional induction of synthesis of the major HDL apolipoproteins (apoa-i and apoa-ii II, lecithin:cholesterol acyltransferase) ) as well as lipoprotein lipase. - decrease in hepatic apoc-iii transcription and enhanced clearance of triglyceride-rich rich lipoproteins.

PPAR and atherosclerosis Levebvre et al. 2006

MI myocardial infarction,, CVA - cerebrovascular accident (stroke), CHD coronary heart disease

Treatment with fibrates reduces cardiovascular risk death or myocardial infarction P=0.006

HDL increase in comparison to baseline Tenenbaum and Fisman 2012

Probability of myocardial infarction during 10 years

PPAR PPAR PPAR is relatively poorly characterized. Its expression is rather ubiquitous, with varying levels in different organs. Endogenous ligand for PPAR is prostacyclin (PGI2) (!). PPAR seems to play a very important role in implantation of embryo. It was also implicated in oligodendrocyte maturation.

PPAR expression in epidermis during wound healing

PPAR wound healing Recent studies have demonstrated an involvement of PPAR in regulation of wound healing. Its activation: * contributes to lipid biosynthesis in sebocytes and keratinocytes * ameliorates inflammatory responses in the skin. * diminishes proliferation and accelerates differentiation of keratinocytes * enhances keratinocyte resistance to apoptotic signals. Increased proliferation and death of keratinocytes at the edges of epidermal wounds in PPAR mutant mice most likely participate in the healing delay observed in these animals.

Effect of PPAR deficiency on keratinocyte adhesion......and in vitro wound healing.

PPAR atherosclerosis Some studies indicate, that activation of PPAR may influence atherogenesis,, although the final output of its action is not known yet. Artificial, selective ligand of PPAR was reported to cause a dramatic rise in HDL cholesterol, while lowering the levels of LDL small dense lipoprotein, fasting triglicerides, and insulin. On the other hand, PPAR,, whose expression is increased during differentiation of macrophages, increases the expression of genes involved in lipid uptake and storage, what may promote the macrophage lipid accumulation and foam cell formation ation.

PPAR overexpressing mice - Overexpression of PPAR in adipose tissue specifically induces expression of genes required for fatty acid oxidation and energy dissipation, which then leads to improved lipid profiles and reduced adiposity. - Importantly, these animals are completely resistant to obesity that is induced by a high- fat diet and by genetic predisposition. - As predicted, treatment of obese mice with a synthetic PPAR agonist depletes lipid accumulation. In parallel, PPAR -deficient mice challenged with a high-fat diet show reduced energy expenditure and are prone to obesity. Maybe PPAR serves as a widespread regulator of fat burning and is a potential target in the treatment of obesity. - The Marathon MiceM are capable of continuous running of up to twice the distance of a wild-type littermate. This is achieved by targeted expression of an activated form of PPAR in skeletal muscle, which resulted in a dramatic increase in "nonfatiguing" nonfatiguing,, red" " type I muscle fibers. marathon mouse

Increased Oxidative Type I Fibers in the PPAR Transgenic Mice Skeletal muscle fibers are generally classified as type I or r type II fibers. Type I fibers (oxidative/slow) are mitochondria rich and mainly use oxidative metabolism for energy production, which provides a stable and long-lasting lasting supply of ATP, and thus are fatigue-resistant. Type II (glycolytic/fast) t) fibers comprise three subtypes, IIa, IIx,, and IIb.. Type IIb fibers have the lowest levels of mitochondrial content and oxidative enzymes, rely on glycolytic metabolism as a major energy source, and are susceptible to fatigue, while the oxidative and contraction functions of type IIa and IIx lie between type I and IIb Metachromatic staining of the plantaris muscle. Type I fibers are stained dark blue. Wang et al. 2004

Skeletal muscles in the PPAR Transgenic Mice Muscles in transgenic mice (TG) are redder than those in wild-type mice (WT) Wang et al. 2004

Effect of PPAR overexpression on obesity Body weight Adipose tissue morphology Wang et al. 2004

Effect of pharmacological activation of PPAR on obesity Old mice fed a high-fat diet Body weight Blood glucose level after glucose injection Wang et al. 2004

Therapeutic targets of PPAR Barish et al. 2006

Thank you and see you next week... What would be profitable to remember in June: - Expression pattern and physiological role of PPARs - Current and potential usage of PPAR ligand in the clinic - Potential clinical significance of PPAR Slides can be found in the library and at the Heme Oxygenase Fan Club page: https://biotka.mol.uj.edu.pl/~hemeoxygenase